TENSIXTEEN BIO
TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases. The company uses somatic mosaicism and clonal hematopoiesis (CHIP) to find and develop new treatments for age-related disorders. Foresite Labs co-founded TenSixteen Bio, which is based in San Francisco.
TENSIXTEEN BIO
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2020-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.tensixteen.bio
Total Employee:
11+
Status:
Active
Total Funding:
40 M USD
Technology used in webpage:
Domain Not Resolving SPF IPv6 Google Google Cloud Google Apps For Business DMARC WP Engine Zendesk Google DNS
Similar Organizations
Sagimet Biosciences
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
TamuroBio
TamuroBio is an operator of a biotechnology company intended to develop novel therapeutics for NAFLD/NASH and Type 2 diabetes.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Google Ventures
Google Ventures investment in Series A - TenSixteen Bio
Foresite Capital
Foresite Capital investment in Series A - TenSixteen Bio
More informations about "TenSixteen Bio"
TenSixteen Bio - LinkedIn
TenSixteen Bio is the first company to leverage somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel therapeutics to treat age-related …See details»
TenSixteen Bio - Funding, Financials, Valuation & Investors
TenSixteen Bio is a biotechnology company focused on developing novel therapeutics for a variety of diseases. Search Crunchbase. Start Free Trial . Chrome Extension. ... How much …See details»
TenSixteen Bio - Foresite Capital
TenSixteen Bio is the first company leveraging somatic mosaicism and clonal hematopoiesis (CHIP) to discover and develop novel therapeutics to treat age-related diseases. A Foresite …See details»
TenSixteen Bio - PitchBook
TenSixteen Bio was founded in 2020. Where is TenSixteen Bio headquartered? TenSixteen Bio is headquartered in South San Francisco, CA. What is the size of TenSixteen Bio? TenSixteen Bio has 11 total employees. What industry is …See details»
TenSixteen Bio Launches with Funding from Foresite …
Jan 27, 2022 TenSixteen Bio is the first company leveraging somatic mosaicism and clonal hematopoiesis (CHIP) to discover and develop novel therapeutics to treat age-related diseases.See details»
TenSixteen Bio - Contacts, Employees, Board Members
Organization. TenSixteen Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. Contacts …See details»
TENSIXTEEN BIO, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for TENSIXTEEN BIO, INC. of South San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
TenSixteen Bio - Craft
TenSixteen Bio is a biotechnology company that develops novel therapeutics to treat age-related diseases. It specializes in leveraging somatic mosaicism and clonal hematopoiesis of …See details»
Tensixteen Bio Inc. - BioCentury Company Profiles - BCIQ
Jan 4, 2024 Tensixteen Bio Inc. - BioCentury Company Profiles for the biopharma industrySee details»
About TenSixteen Bio - Medium
Read more about TenSixteen Bio. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential (CHIP) to discover and develop novel …See details»
Announcing TenSixteen Bio, a Pioneering Company to Pursue the …
Jan 27, 2022 If you are interested in joining us please reach out at tensixteen.bio website. Mark Chao MD, PhD. Co-founder and CEO of Tensixteen Bio. Life Sciences. Healthcare. Startup. …See details»
Foresite and GV pour $40M into startup’s move to CHIP
Jan 27, 2022 TenSixteen Bio has emerged from stealth aiming to develop drugs for diseases caused by genetic mutations accumulated as we age. The startup has been incubating within …See details»
TenSixteen Bio Launches With $40M Series A To Advance A New …
Jan 27, 2022 Biosciences startup TenSixteen Bio launched Thursday with a $40 million Series A round funded by Foresite Capital and GV, formerly Google Ventures. The San Francisco …See details»
Mark Chao - Co-Founder and CEO @ TenSixteen Bio - Crunchbase
Primary Organization . TenSixteen Bio . Location San Francisco, California, United States; ... Mark Chao is the Co-founder and CEO of TenSixteen Bio and he earned his MD and PhD in …See details»
BioCentury - TenSixteen: Targeting dynamic genome to find driver ...
Jan 28, 2022 TenSixteen Bio is launching with a $40 million series A round to interrogate a new source of disease-causing mutations in hematopoietic stem cells that could help stop the …See details»
Latest stories published on TenSixteen Bio – Medium
Jan 27, 2022 Read the latest stories published by TenSixteen Bio. TenSixteen is the first company leveraging somatic mosaicism and clonal hematopoiesis of indeterminate potential …See details»
TenSixteen Bio launches with $40 million to treat age-related disease
Jan 29, 2022 TenSixteen Bio has launched with $40 million from Foresite Capital and GV (formerly Google Ventures) to treat age-related diseases. ... TenSixteen was founded by CEO …See details»
Precision genomics startup Tensixteen Bio launches with $40M
Jan 27, 2022 Investors have backed a new precision medicine company targeting clonal hematopoiesis with $40 million. Tensixteen Bio Inc. is on a mission to understand how somatic …See details»
Pharma Startup TenSixteen Bio Developing Drugs, Companion …
Feb 16, 2022 NEW YORK – Backed by a recent $40 million in funding from Foresite Capital and GV (formerly Google Ventures), San Francisco-based TenSixteen Bio is exploring clonal …See details»